ICD-10 Coding for Cancer Antigen 125(C56.9, C56.9B, C56.9M)
Learn about ICD-10 coding for elevated Cancer Antigen 125 (CA-125), including code R97.1, documentation requirements, and clinical guidelines.
Complete code families applicable to Cancer Antigen 125
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| R97.1 | Elevated cancer antigen 125 [CA 125] | Use when CA-125 is elevated and not directly linked to a confirmed malignancy. |
|
| C56.9 | Malignant neoplasm of ovary, unspecified | Use as a primary code when CA-125 is used for monitoring ovarian cancer. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutCancer Antigen 125
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Cancer Antigen 125.
Failing to document clinical context for CA-125 testing
Impact
Clinical: May lead to misinterpretation of test results., Regulatory: Non-compliance with documentation standards., Financial: Potential claim denials due to lack of justification.
Mitigation
Always include clinical indication in the patient's record., Use templates to ensure completeness.
Using R97.1 as a primary code for cancer monitoring
Impact
Reimbursement: Incorrect sequencing can lead to claim denials., Compliance: Non-compliance with coding guidelines., Data Quality: Affects accuracy of cancer registry data.
Mitigation
Always sequence the malignancy code first, followed by R97.1.
Incorrect sequencing of codes
Impact
R97.1 used as primary code for cancer monitoring.
Mitigation
Educate coders on proper sequencing rules.